Background The prognosis of hepatocellular carcinoma (HCC) patients with extrahepatic metastasis is extremely poor. However, what is the main risk factor for survival remains unclear for these patients. We aimed to find out the relative frequency, incidence and locations of extrahepatic metastases and the risk factors of long-term survival of the patients. Methods 132 HCC patients with extrahepatic metastasis diagnosed by 18F-FDG PET/CT and conventional workup were enrolled into this study. The incidence and locations of extrahepatic metastases were summarized, and the related risk factors of overall survival were analyzed. Results The most frequent extrahepatic metastatic sites were lymph nodes in 72 (54.5%), bone in 33 (25.0%) and lung in 28 (21.2%) patients. On univariate analysis, prothrombin time, Child-Pugh grade, portal/hepatic vein invasion and lymph node metastasis were independent risk factors of overall survival. On multivariate analysis, lymph node metastasis was the only independent risk factor of overall survival. The cumulative survival rates at 1- and 3-years after diagnosis of extrahepatic metastasis of HCC were 34.4% and 9.3%, respectively. The median survival time was 7 months (range 1 ~38 months). The median survival time for patients with or without lymph node metastasis were 5 months (range 1~38 months) and 12 months (range 1~30 months), respectively (P = 0.036). Conclusions This study showed lymph nodes to be the most frequent site of extrahepatic metastases for primary HCC. Lymph node metastasis was the main risk factor of overall survival in patients with HCC with extrahepatic metastasis.
References
[1]
Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin 61: 69–90. doi: 10.3322/caac.20107
[2]
Katyal S, Oliver JH 3rd, Peterson MS, Ferris JV, Carr BS, et al. (2000) Extrahepatic metastases of hepatocellular carcinoma. Radiology 216: 698–703. doi: 10.1148/radiology.216.3.r00se24698
[3]
Shuto T, Hirohashi K, Kubo S, Tanaka H, Yamamoto T, et al. (2001) Treatment of adrenal metastases after hepatic resection of a hepatocellular carcinoma. Dig Surg 18: 294–297. doi: 10.1159/000050155
[4]
Si MS, Amersi F, Golish SR, Ortiz JA, Zaky J, et al. (2003) Prevalence of metastases in hepatocellular carcinoma: risk factors and impact on survival. Am Surg 69: 879–885.
Yoon KT, Kim JK, Kim do Y, Ahn SH, Lee JD, et al. (2007) Role of 18F-fluorodeoxyglucose positron emission tomography in detecting extrahepatic metastasis in pretreatment staging of hepatocellular carcinoma. Oncology 72 Suppl 1104–110. doi: 10.1159/000111715
[7]
Llovet JM, Real MI, Montana X, Planas R, Coll S, et al. (2002) Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359: 1734–1739. doi: 10.1016/s0140-6736(02)08649-x
[8]
Kim YK, Lee KW, Cho SY, Han SS, Kim SH, et al. (2010) Usefulness 18F-FDG positron emission tomography/computed tomography for detecting recurrence of hepatocellular carcinoma in posttransplant patients. Liver Transpl 16: 767–772. doi: 10.1002/lt.22069
[9]
Kawaoka T, Aikata H, Takaki S, Uka K, Azakami T, et al. (2009) FDG positron emission tomography/computed tomography for the detection of extrahepatic metastases from hepatocellular carcinoma. Hepatol Res 39: 134–142. doi: 10.1111/j.1872-034x.2008.00416.x
[10]
He YX, Guo QY (2008) Clinical applications and advances of positron emission tomography with fluorine-18-fluorodeoxyglucose (18F-FDG) in the diagnosis of liver neoplasms. Postgrad Med J 84: 246–251. doi: 10.1136/pgmj.2007.066589
[11]
Wudel LJ Jr, Delbeke D, Morris D, Rice M, Washington MK, et al. (2003) The role of [18F]fluorodeoxyglucose positron emission tomography imaging in the evaluation of hepatocellular carcinoma. Am Surg 69: 117–124 discussion 124–116.
[12]
Ho CL, Chen S, Yeung DW, Cheng TK (2007) Dual-tracer PET/CT imaging in evaluation of metastatic hepatocellular carcinoma. J Nucl Med 48: 902–909. doi: 10.2967/jnumed.106.036673
[13]
Sugiyama M, Sakahara H, Torizuka T, Kanno T, Nakamura F, et al. (2004) 18F-FDG PET in the detection of extrahepatic metastases from hepatocellular carcinoma. J Gastroenterol 39: 961–968. doi: 10.1007/s00535-004-1427-5
[14]
Lin CY, Chen JH, Liang JA, Lin CC, Jeng LB, et al. (2012) 18F-FDG PET or PET/CT for detecting extrahepatic metastases or recurrent hepatocellular carcinoma: a systematic review and meta-analysis. Eur J Radiol 81: 2417–2422. doi: 10.1016/j.ejrad.2011.08.004
[15]
Natsuizaka M, Omura T, Akaike T, Kuwata Y, Yamazaki K, et al. (2005) Clinical features of hepatocellular carcinoma with extrahepatic metastases. J Gastroenterol Hepatol 20: 1781–1787. doi: 10.1111/j.1440-1746.2005.03919.x
[16]
Ochiai T, Ikoma H, Okamoto K, Kokuba Y, Sonoyama T, et al. (2012) Clinicopathologic features and risk factors for extrahepatic recurrences of hepatocellular carcinoma after curative resection. World J Surg 36: 136–143. doi: 10.1007/s00268-011-1317-y
[17]
Tanaka K, Shimada H, Matsuo K, Takeda K, Nagano Y, et al. (2008) Clinical features of hepatocellular carcinoma developing extrahepatic recurrences after curative resection. World J Surg 32: 1738–1747. doi: 10.1007/s00268-008-9613-x
[18]
Chan KM, Yu MC, Wu TJ, Lee CF, Chen TC, et al. (2009) Efficacy of surgical resection in management of isolated extrahepatic metastases of hepatocellular carcinoma. World J Gastroenterol 15: 5481–5488. doi: 10.3748/wjg.15.5481
[19]
Taketomi A, Toshima T, Kitagawa D, Motomura T, Takeishi K, et al. (2010) Predictors of extrahepatic recurrence after curative hepatectomy for hepatocellular carcinoma. Ann Surg Oncol 17: 2740–2746. doi: 10.1245/s10434-010-1076-2
[20]
Sun HC, Zhuang PY, Qin LX, Ye QH, Wang L, et al. (2007) Incidence and prognostic values of lymph node metastasis in operable hepatocellular carcinoma and evaluation of routine complete lymphadenectomy. J Surg Oncol 96: 37–45. doi: 10.1002/jso.20772
[21]
Primary liver cancer in Japan. Clinicopathologic features and results of surgical treatment. Ann Surg 211: 277–287.
[22]
Lee CW, Chan KM, Lee CF, Yu MC, Lee WC, et al. (2011) Hepatic resection for hepatocellular carcinoma with lymph node metastasis: clinicopathological analysis and survival outcome. Asian J Surg 34: 53–62. doi: 10.1016/s1015-9584(11)60020-1
[23]
Xiaohong S, Huikai L, Feng W, Ti Z, Yunlong C, et al. (2010) Clinical significance of lymph node metastasis in patients undergoing partial hepatectomy for hepatocellular carcinoma. World J Surg 34: 1028–1033. doi: 10.1007/s00268-010-0400-0
[24]
Ercolani G, Grazi GL, Ravaioli M, Grigioni WF, Cescon M, et al. (2004) The role of lymphadenectomy for liver tumors: further considerations on the appropriateness of treatment strategy. Ann Surg 239: 202–209. doi: 10.1097/01.sla.0000109154.00020.e0
[25]
Uka K, Aikata H, Takaki S, Shirakawa H, Jeong SC, et al. (2007) Clinical features and prognosis of patients with extrahepatic metastases from hepatocellular carcinoma. World J Gastroenterol 13: 414–420.
[26]
Lee CY, Bae MK, Park IK, Kim DJ, Lee JG, et al. (2010) Surgical resection for pulmonary metastasis from hepatocellular carcinoma: analysis of prognosis in relation to primary control. J Surg Oncol 101: 239–243. doi: 10.1002/jso.21487
[27]
Sakamoto M, Murakawa T, Kitano K, Murayama T, Tsuchiya T, et al. (2010) Resection of solitary pulmonary lesion is beneficial to patients with a history of malignancy. Ann Thorac Surg 90: 1766–1771. doi: 10.1016/j.athoracsur.2010.07.054
[28]
Yoon YS, Kim HK, Kim J, Choi YS, Shim YM, et al. (2010) Long-term survival and prognostic factors after pulmonary metastasectomy in hepatocellular carcinoma. Ann Surg Oncol 17: 2795–2801. doi: 10.1245/s10434-010-1073-5
[29]
Kitano K, Murayama T, Sakamoto M, Nagayama K, Ueno K, et al. (2012) Outcome and survival analysis of pulmonary metastasectomy for hepatocellular carcinoma. Eur J Cardiothorac Surg 41: 376–382. doi: 10.1016/j.ejcts.2011.05.052
